山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2015年
23期
12-14
,共3页
刘静%张柳%杨勇%李春燕%龚平%郭华雄
劉靜%張柳%楊勇%李春燕%龔平%郭華雄
류정%장류%양용%리춘연%공평%곽화웅
卵巢肿瘤%卵巢癌%CXC家族趋化因子受体4%基质金属蛋白酶9
卵巢腫瘤%卵巢癌%CXC傢族趨化因子受體4%基質金屬蛋白酶9
란소종류%란소암%CXC가족추화인자수체4%기질금속단백매9
ovarian neoplasms%ovarian carcinoma%CXC chemokine receptor 4%matrix metalloproteinase 9
目的:观察卵巢癌组织中CXC家族趋化因子受体4(CXCR4)、基质金属蛋白酶9(MMP-9)的表达变化,并探讨其意义。方法采用免疫组化法检测60例份卵巢癌( A组)、20例份交界性肿瘤( B组)、10例份良性肿瘤( C组)组织CXCR4、MMP-9,并分析两者间及其与卵巢癌临床病理参数的相关性。结果 A、B、C组CXCR4阳性率分别为58.33%(35/60)、20.00%(4/20)、10.00%(1/10),A组分别与B、C组比较,P均<0.05;MMP-9阳性率分别为83.33%(50/60)、35.00%(7/20)、20.00%(2/10),A组分别与B、C组比较,P均<0.05。 CXCR4表达与卵巢癌TNM分期、淋巴结转移有关,MMP-9表达与卵巢癌组织学分级、TNM分期、淋巴结转移有关(P均<0.05)。卵巢癌组织中CXCR4与MMP-9表达呈正相关( r=0.257,P<0.05)。结论卵巢癌组织中CXCR4、MMP-9表达升高,其可能在卵巢癌的发生发展过程中起重要作用,联合检测二者可为寻找卵巢癌靶向治疗提供实验依据。
目的:觀察卵巢癌組織中CXC傢族趨化因子受體4(CXCR4)、基質金屬蛋白酶9(MMP-9)的錶達變化,併探討其意義。方法採用免疫組化法檢測60例份卵巢癌( A組)、20例份交界性腫瘤( B組)、10例份良性腫瘤( C組)組織CXCR4、MMP-9,併分析兩者間及其與卵巢癌臨床病理參數的相關性。結果 A、B、C組CXCR4暘性率分彆為58.33%(35/60)、20.00%(4/20)、10.00%(1/10),A組分彆與B、C組比較,P均<0.05;MMP-9暘性率分彆為83.33%(50/60)、35.00%(7/20)、20.00%(2/10),A組分彆與B、C組比較,P均<0.05。 CXCR4錶達與卵巢癌TNM分期、淋巴結轉移有關,MMP-9錶達與卵巢癌組織學分級、TNM分期、淋巴結轉移有關(P均<0.05)。卵巢癌組織中CXCR4與MMP-9錶達呈正相關( r=0.257,P<0.05)。結論卵巢癌組織中CXCR4、MMP-9錶達升高,其可能在卵巢癌的髮生髮展過程中起重要作用,聯閤檢測二者可為尋找卵巢癌靶嚮治療提供實驗依據。
목적:관찰란소암조직중CXC가족추화인자수체4(CXCR4)、기질금속단백매9(MMP-9)적표체변화,병탐토기의의。방법채용면역조화법검측60례빈란소암( A조)、20례빈교계성종류( B조)、10례빈량성종류( C조)조직CXCR4、MMP-9,병분석량자간급기여란소암림상병리삼수적상관성。결과 A、B、C조CXCR4양성솔분별위58.33%(35/60)、20.00%(4/20)、10.00%(1/10),A조분별여B、C조비교,P균<0.05;MMP-9양성솔분별위83.33%(50/60)、35.00%(7/20)、20.00%(2/10),A조분별여B、C조비교,P균<0.05。 CXCR4표체여란소암TNM분기、림파결전이유관,MMP-9표체여란소암조직학분급、TNM분기、림파결전이유관(P균<0.05)。란소암조직중CXCR4여MMP-9표체정정상관( r=0.257,P<0.05)。결론란소암조직중CXCR4、MMP-9표체승고,기가능재란소암적발생발전과정중기중요작용,연합검측이자가위심조란소암파향치료제공실험의거。
Objective To observe the expression changes of CXC chemokine receptor 4 (CXCR4) and matrix metal-loproteinase 9 ( MMP-9) in ovarian carcinoma tissues, and to investigate their clinical significance.Methods The expres-sion of CXCR4 and MMP-9 in 60 cases of ovarian carcinoma ( group A) , 20 cases of borderline tumor ( group B) and 10 cases of benign tumor ( group C) was examined by immunohistochemical method.The correlation between them and their correlations with the clinicopathological parameters were analyzed.Results The positive expression rates of CXCR4 in the group A, group B and group C were 58.33%(35/60), 20.00%(4/20) and 10.00%(1/10), respectively.There was a statistically significant difference between group A and groups B and C (all P<0.05).The positive expression rates of MMP-9 in the group A, group B and group C were 83.33% (50/60), 35.00%(7/20) and 20.00% (2/10), respec-tively.Significant difference was found when we compared group A with groups B and C (all P<0.05).In ovarian carci-noma, the expression of CXCR4 protein was related with TNM stage and lymph-node metastasis;the expression of MMP-9 protein was related with tumor histological grade, TNM stage and lymph-node metastasis ( all P<0.05) .The CXCR4 ex-pression was positively correlated with the expression of MMP-9 in the ovarian carcinoma tissues (r=0.257, P<0.05). Conclusions The expression of CXCR4 and MMP-9 is increased in the ovarian carcinoma tissues, which may play an im-portant role in the carcinogenesis and development of ovarian carcinoma.The combined detection of CXCR4 and MMP-9 may provide scientific experimental evidence for targeted therapy.